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Late Passage Human Fibroblasts Induced to Pluripotency
Are Capable of Directed Neuronal Differentiation
Jun Liu,* Huseyin Sumer,* Jessie Leung,† Kyle Upton,*
Mirella Dottori,†‡ Alice Pébay,†‡ and Paul J. Verma*
*Centre for Reproduction and Development, Monash Institute of Medical Research, Monash University, Clayton, Victoria, Australia
†Centre for Neuroscience, The University of Melbourne, Parkville, Victoria, Australia
‡Department of Pharmacology, The University of Melbourne, Parkville, Victoria, Australia
It is possible to generate induced pluripotent stem (iPS) cells from mouse and human somatic cells by
ectopic expression of defined sets of transcription factors. However, the recommendation that somatic cells
should be utilized at early passages for induced reprogramming limits their therapeutic application. Here we
report successful reprogramming of human fibroblasts after more than 20 passages in vitro, to a pluripotent
state with four transcription factors: Oct4, Sox2, Klf4, and c-Myc. The late passage-derived human iPS cells
resemble human embryonic stem cells in morphology, cell surface antigens, pluripotent gene expression
profiles, and epigenetic states. Moreover, these iPS cells differentiate into cell types representative of the
three germ layers in teratomas in vivo, and directed neuronal differentiation in vitro.
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INTRODUCTION tors. c-Myc has been shown to enhance proliferation and
transformation (2). It also may induce global histone
acetylation (12), thus allowing Oct4 and Sox2 to bind toThe generation of human embryonic stem (hES) cells
with the ability to differentiate into all cell types of the their specific target loci. Klf4 has been shown to repress
p53 expression (43), and p53 protein is related with Na-body opened up an exciting opportunity for cell-based
transplantation therapy for regenerative diseases (5,21). nog suppression during ES cell differentiation (26).
Other combinations of transcription factors, such asHowever, an ideal requirement for stem cell-based ther-
apy is to use stem cells derived from patients to circum- Nanog and Lin28 combined with Oct3/4 and Sox2, are
also capable of inducing reprogramming of somatic cellsvent immune rejection of the cells following transplanta-
tion. Transfer of a somatic cell nucleus to an enucleated (55). In addition to the fibroblasts used in the above
mentioned studies, other cell types, including keratino-oocyte [somatic cell nuclear transfer (SCNT)] and acti-
vation and development of the resulting SCNT embryo cytes (1,31), liver cells (3,45), lymphocytes (14), neural
progenitors/stem cells (11,23), pancreatic β-cells (45),to the blastocyst stage embryo allowed derivation of do-
nor-specific embryonic stem cells in rodents and pri- and stomach cells (3), have been reprogrammed by ex-
ogenous expression of the four transcription factors. iPSmates, but as yet not in humans.
Recently it has been shown that forced expression of cells have been generated from patients of genetically
inherited diseases as an alternative to therapeutic cloningfour transcription factors, namely Oct3/4, Sox2, Klf4,
and c-Myc (OSKM), in human fibroblasts can repro- or SCNT for the generation of patient-specific pluripo-
tent stem cells (8,10,30,37,41).gram the cells to a pluripotent state. These induced plur-
ipotent stem (iPS) cells exhibit the morphology and cell The source of donor cells is one of the concerns for
direct pluripotent reprogramming. Recently we havecycle properties of hES cells, the expression of hES cell
marker genes, and formation of teratomas in immunode- identified cell types in the mouse that reprogram very
efficiently with a reprogramming rate of 1.14% (49).ficient mice (7,8,17,29,39,44,48). Oct4 and Sox2 have
been shown to play a key role in maintaining pluripo- However, typically the generation of iPS cells is still
inefficient, ranging between 0.01% and 0.2% when us-tency (6,28). c-Myc and Klf4 are two tumor-related fac-
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ing directed retroviral infection of adult cells with vec- 29-gauge needle, and then transfer them to a fresh MEF
layer. Enzymatic dissociation was performed by incubat-tors expressing OSKM. Therefore, it is necessary to be-
gin infection with a large amount of cells. Practically, it ing the iPS cell culture with 4 mg/ml dispase (In-
vitrogen) at 37°C for 10 min. The detached colonieswould be difficult to harvest enough cells from a normal
clinical biopsy (6 mm) in less than three passages, were pipetted up and down to dissociate them into small
pieces, and then centrifuged at 300 × g for 5 min. Thewhich is the recommended passage for reliable repro-
gramming (32,38). In this study, we examined whether pellet was resuspended and cultured on a fresh MEF
layer in the hES cell medium containing 10 mM Y-late passage human fibroblasts could be reprogrammed
to pluripotency by the four factors: OSKM. We exam- 27632 (Calbiochem), a ROCK inhibitor (52), for 24 h,
before returning to standard hES cell medium.ined whether late passage-derived human iPS cells re-
sembled human ES cells in morphology, cell surface
Feeder Preparationantigens, pluripotent gene expression profiles, and epi-
genetic states. In addition, we investigated the ability of MEFs were isolated from day 13.5 postcoitum fe-
tuses of CD1 mice. They were treated with 10 µg/mlthese iPS cells to differentiate randomly in vivo into
cells representative of the three germ layers in terato- mitomycin C (Sigma) for 3 h to arrest mitosis, then
washed in PBS, and replated at a density of 4 × 104 cells/mas, and by directed neuronal and neural crest differen-
tiation in vitro. cm2 on gelatin (Sigma)-coated tissue culture dishes.
Retroviral Production and iPS Cell Generation
MATERIALS AND METHODS
Moloney-based retroviral vectors (pMXs) containing
Animals the human cDNAs of OCT4, SOX2, KLF4 and c-MYC
All mice were housed at the Monash Medical Centre were obtained from Addgene (www.addgene.org). Nine
Animal Facilities, Clayton, Australia. SCID mice were microgram of each plasmid was transfected into viral
housed in specific pathogen-free (SPF) conditions. All packaging Plat-A cells using Fugene 6 (Roche). Virus-
animal experimentation was conducted with protocols containing supernatants were collected 48 and 72 h post-
and ethics approved by the Monash Medical Centre Ani- transfection and filtered through a 0.45-µm pore size
mal Welfare Committee. filter and supplemented with 4 µg/ml of polybrene
(Sigma). D551 cells at passage 23 were plated 24 h prior
Cell Culture to infection at a density of 1 × 104 cells/cm2. Retroviral
Human fibroblast Detroit 551 (D551) cells were ob- supernatants of four transcription factors were mixed in
tained from ATCC (www.atcc.com). Retroviral packag- equal quantities and added to the target cells at 24 and
ing Platinum-A (Plat-A) cells, a transfected human em- 48 h. The culture medium for the infected cells was
bryonic kidney (HEK)-293T cell line, were obtained changed to hES cell medium at day 4 postinfection. The
from Cell Biolabs, Inc. (www.cellbiolabs.com). Mouse cells were maintained in the culture with medium re-
embryonic fibroblasts (MEFs), D551 cells, and Plat-A freshment every day up to about 4 weeks or until the
cells were cultured in Dulbecco’s modified eagle me- cells reached over confluence, in which case the cells
dium (DMEM, Invitrogen) supplemented with 10% fetal were replated on a MEF feeder layer. To establish iPS
bovine serum (FBS, Invitrogen). Human embryonic cell lines, iPS cell colonies were picked-up based on
stem (hES) cell line, MEL-1, was obtained from Austra- hES cell-like colony morphology at about 4 weeks post-
lia Stem Cell Centre (ASCC) and cultured in DMEM infection. The picked colonies were expanded on fresh
supplemented with 20% FBS (Hyclone), 1 mM L-Gluta- MEF feeder layer in hES cell medium. To estimate
max, 0.1 mM nonessential amino acids, 0.1 mM β-mer- transduction efficiency of D551 cells, pMXs-GFP retro-
captoethanol, 1% ITS, and 10 ng/ml bFGF (all from In- viral vectors were also transfected to Plat-A cells using
vitrogen). Human iPS cells were cultured in the medium the same method as described above. pMXs retroviruses
described above for MEL-1 cells with changing culture containing the GFP cDNA were added to D551 cells.
medium daily. Human iPS cell lines, ES4CL1-4 and The number of cells expressing GFP was evaluated by
MR90, were kindly provided by Prof. J. Thomson (Ge- flow cytometry 48 h after infection.
nome Center of Wisconsin, Madison, WI) and used in
FACS Analysisthe study.
For passaging of the cells, either mechanical dissocia- Cells were dissociated with 0.25% trypsin-EDTA (In-
tion or enzymatic digestion was used. Mechanical disso- vitrogen) for 5 min. Resuspended cells were filtered
ciation was performed to dissect iPS cell colonies into through a 40-µm cell strainer (BD Falcon) and analyzed
smaller cell clumps using a 1-ml insulin syringe with a using a BD FACSCanto flow cytometer (BD).
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Karyotype Analysis washes with PBS. Alkaline phosphatase (AP) staining
was performed using the Alkaline Phosphatase Detec-Karyotype analysis was performed in the Cytogenet-
tion Kit (Millipore), according to the manufacturer’s in-ics, Monash Medical Centre. Briefly, the cells were
structions. For immunofluorescence, cells were blockedgrown to subconfluency at which point colcemid (In-
with 10% goat serum (Sigma) in PBS/0.1% Triton Xvitrogen) was added to a final concentration of 0.1 mg/
and incubated with primary antibodies overnight at 4°C.ml for 30–60 min. Cells were then trypsinized, pelleted
Secondary antibodies were incubated for 1 h at roomby centrifugation at 1,200 rpm for 5 min, resuspended
temperature. The primary antibodies included pluripo-in 2 ml of hypotonic solution (0.56% KCl + 0.5% Na
tent stem cell makers: Oct4 (Santa Cruz Biotechnology),citrate), and incubated for 30 min in a 37°C water bath.
SSEA3, SSEA4, Tra-1-60, Tra-1-81 (all from Millipore),After pelleting of cells again by centrifugation, the su-
and neural differentiation makers: β-tubulin (Millipore),pernatant was removed and ice-cold fresh fixative com-
Pax-6 (Developmental Studies Hybridoma Bank), p75prised of one part acetic acid to three parts methanol
(Sigma), and Peripherin (Sigma). Appropriate Alexawas added drop-wise to a final volume of 10 ml. Cells
Fluor 594 or 488 conjugated secondary antibodies (In-were fixed for 10 min at −20°C, pelleted by centrifuga-
vitrogen) were used to visualize immunoreaction. Nucleition, supernatant was removed, and 2 ml fresh fixative
were counterstained with 1 µg/ml of Hoechst-33342added. Metaphases from cells prepared in this manner
(Sigma-Aldrich) in some slides. The negative controlwere assessed by G-banding. At least 20 metaphase
was performed following the whole procedure describedspreads were evaluated.
above except replacing the primary antibodies with
blocking solution.RT-PCR and PCR
Total RNA was isolated using RNeasy kit (Qiagen)
Bisulfite Genomic Sequencingand cleaned using DNA-free kit (Ambion) followed by
cDNA synthesis using Superscript III Reverse Tran- Genomic DNA (1 µg) from human iPS cells, MEL-1
scriptase and Oligo (dT) primers (Invitrogen). Genomic cells, and D551 cells were processed for bisulfite modi-
DNA was isolated using DNeasy Blood & Tissue kit fication using CpGemone DNA modification kit (Milli-
(Qiagen). PCR was performed with Taq DNA polymer- pore). Two conserved CpG-enriched regions in the Oct4
ase (Invitrogen). Primer sequences are supplied in Table 1. promoter and one conserved CpG-enriched region in the
Nanog promoter were selected to be amplified by PCR
Alkaline Phosphatase and Immunofluorescence Staining (13). The PCR products were subcloned into pGEMT-
easy vector (Promega). Ten clones of each sample wereCells were fixed in 4% paraformaldehyde (Sigma) in
PBS for 20 min at room temperature followed by three verified by sequencing with Sp6 universal primer and
Table 1. Primers for RT-PCR and PCR Reactions
Gene Name Forward Primer (5′ to 3′) Reverse Primer (5′ to 3′)








Oct3/4 (transgene) CTAGTTAATTAAGAATCCCAGTG CACTAGCCCCACTCCAACCT
Sox2 (transgene) CTAGTTAATTAAGGATCCCAGG TGTTGTGCATCTTGGGGTTCT
Klf4 (transgene) ACAAAGAGTTCCCATCTCAAGGTG TCCAAGCTAGCTTGCCAAACCTACAGG
c-Myc (transgene) CTAGTTAATTAAGGATCCCAGTG CAGCAGCTCGAATTTCTTCC
For bisulphite-sequencing
PCR
Oct3/4 (1) GGATGTTATTAAGATGAAGATAGTTGG CCTAAACTCCCCTTCAAAATCTATT
Oct3/4 (2) TAGTTGGGATGTGTAGAGTTTGAGA TAAACCAAAACAATCCTTCTACTCC
Nanog GAGTTAAAGAGTTTTGTTTTTAAAAATTAT TCCCAAATCTAATAATTTATCATATCTTTC
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Figure 1. Generation of iPS cells from passage 23 D551 cells. (A) D551 cells at passage 23 were introduced with pMXs retroviruses
containing GFP cDNAs. (A-a) Phase contrast image of D551 cells; (A-b) shows the images of GFP fluorescence of the same cells,
and (A-c) is the merged image of A-a and A-b. (B) Progression of cell morphology changes from fibroblasts to iPS cells. (a) D551
cells at day 1 when receiving retroviruses containing 4 reprogramming factors. (b, c) 19 days after infection, type 1 and type 2
hES cell-like colonies (dotted areas), respectively. (d) 26 days after infection, typical image of hES cell-like colony. (e) AUS cells
at passage 1 on the MEF feeder cells by mechanical dissociation. The image was taken at day 2 after passaging. (f) AUS cells at
passage 2,;the image was taken at day 4 after passaging. (g) AUS cells at passage 4 by Dispase dissociation. The image was taken
at day 2 after passaging. (h) AUS cells at passage 4 in higher magnification (40×). Scale bars: 200 µm.
the methylation status was determined using BiQ Ana- in 96-well plates for each cell line in one experiment.
We performed at least two replicates. Medium waslyzer software (4). Primers used for PCR amplification
were provided in Table 1. changed every second day. The frequency of neurosph-
ere formation was measured after 7 days of culture as
Teratoma Formation determined by spherical cluster of cells showing pres-
ence of rosette-like structures. After 14 days of cultureHuman iPS cells grown on MEF feeder layers were
dissociated by dispase treatment, centrifuged, and in- in suspension, the iPSC-derived neurospheres were
plated onto laminin-coated dishes in NBM for 5 days tojected into hind leg muscle of diabetes severe-combined
immunodeficient (NOD-SCID) mice. Teratoma tissues induce their differentiation towards neurons (42). Differ-
entiation towards neural crest-like cells was performedwere collected 6–8 weeks postinjection, and processed
for paraffin embedding and hemaoxylin and eosin using previously published protocols (16). Briefly, iPS-
derived neurospheres were plated onto a feeder layer of(H&E) staining following standard procedures.
MEFs in NBM supplemented with bFGF and EGF
Neurosphere Formation and Neuronal Induction (20ng/ml each). After 24 h, cultures were treated with
the small molecule Rho/ROCK inhibitor Y27632 at aThe human iPS cell lines, AUS-1, ES4CL1-4, and
MR90 (50,55) were treated with 500 ng/ml of Noggin final concentration of 25 µM. After 7 days, cultures
were fixed with 4% paraformaldehyde and processed(R&D) for 14 days to induce their differentiation toward
neuroectoderm, as described elsewhere (9,40). Noggin- immunostaining.
treated cells were mechanically cut into small pieces,
RESULTSand each piece was then further subcultured in 96-well
plates in neural basal media (NBM) supplemented with In this study, we investigated generation of human
iPS cells from a human fibroblast line, Detroit 551basic fibroblast growth factor (bFGF) and epidermal
growth factor (EGF) (20 ng/ml each, R&D) to induce (D551), at passage 23. D551 fibroblasts have a finite life
span of about 25 serial passages from the tissue of ori-neurosphere formation. We plated 24 pieces in 24 wells
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gin. We used Plat-A cell line as a potent retrovirus pack- displayed a single layer of cells. Both types of colonies
could grow to large colonies and be picked up mechani-aging cell line. We transfected Plat-A cells with retrovi-
ral vector pMXs containing open reading frame of human cally and expand on fresh MEF feeder layers at around
4 weeks after infection. The expanded ES-like iPS colo-transcription factors Oct3/4, Sox2, Klf4, and c-Myc. We
collected and introduced the retroviruses containing the nies exhibited a flat and tightly compacted morphology
with distinct edges (Fig. 1B), and the cells exhibited afour factors into the D551 cells. We infected pMX-GFP-
expressing retroviruses into the D551 cells to monitor large nucleus with prominent nucleoli (Fig. 1B), similar
to MEL-1 cells, a human ES cell line, cultured in ourthe viral infection efficiency (Fig. 1A). The single-factor
infection efficiency was about 24.5%, as determined by laboratory (27). The cells were passaged every 4–6
days, which is similar in growth rate to the MEL-1 cells.GFP expression in the cells by FACS analysis. The cells
were refreshed with hES medium 4 days after infection. Three hES cell-like iPS cell lines were expanded and
named AUS-1, -2, and -3, respectively.Nine days following infection, the fibroblasts displayed
primary morphological changes with cell clumping. By We first characterized the AUS cells to test the ex-
pression of pluripotent stem cell markers. All three ex-19 days following infection, two types of cell colonies,
which resembled hES cell colony morphologies with a panded AUS cell lines were positive for the expression
of AP, Oct3/4, SSEA3, SSEA4, TRA-1-60, and TRA-1-high nucleus/cytoplasm ratio (Fig. 1B), could be found
in the cultured cells. Type 1 colonies were comprised 81 (Fig. 2A).
RT-PCR analysis showed that the AUS lines ex-of multilayers of compacted cells and type 2 colonies
Figure 2. Characterization of AUS cells. (A) AUS cells were positive for AP, Oct4, SSEA3, SSEA4, TRA-1-60, and TRA-1-81.
Scale bars: 200 µm. (B) RT-PCR showed that induced human iPS cell lines (AUS-1, AUS-2, and AUS-3) expressed endogenous
human ES cell marker genes, such as Oct4, Sox2, Nanog, and Rex1. Exogenous Oct4, Sox2, and c-Myc genes were effectively
silenced, while the exogenous Klf4 transgene was still expressed. Endo, endogenous; Exo, exogenous. (C) Integration of Oct4,
Sox2, Klf4, and c-Myc transgenes in the genome of AUS cell lines was confirmed by genomic DNA PCR using transgene-specific
primers, with D551 and MEL-1 cells as negative controls, and the respective vector as a positive control.
198 LIU ET AL.
promoter and one CpG-enriched region in Nanog pro-
moter were selected for analysis. Bisulphate genomic se-
quencing analysis showed that both the Oct4 and the
Nanog promoter regions were demethylated in the AUS
cells, similar to human ES cells (MEL-1), whereas the
same regions were highly methylated in parental D551
cells (Fig. 3).
We performed karyotype analysis on two AUS cell
lines and the result showed that both lines maintained a
normal karyotype (46, XX) (Fig. 4A, B).
We evaluated the in vivo differentiation capacity of
AUS cells by teratoma formation. AUS cells formed ter-
atomas after intramuscular injection into hind legs of
NOD-SCID mice. H&E staining of the teratomas re-
vealed that teratomas contained three germ layer tissues,
including secretary gland (endoderm), epidermal tissue
(ectoderm), and cartilage (mesoderm) (Fig. 5a–c).
We then evaluated the in vitro differentiation capac-
ity of all three AUS cell lines by formation of embryoid
bodies (EBs) in suspension culture. All the AUS cells
formed EBs after 7 days of culture (Fig. 5d) and differ-
entiated into different cell types and structures (Fig. 5e)
after attachment for 5 days. To evaluate the in vitro-
directed differentiation capacity of AUS cells, we ap-
plied a directed neuronal differentiation protocol to in-
duce the AUS-1 cells to neuronal lineage. Similar to
hES cells (data not shown), AUS cells were responsive
to Noggin treatment and able to differentiate into neu-
roectoderm, as shown by expression of Pax6 (Fig. 6a).Figure 3. Bisulfite sequencing analysis of Oct4 and Nanog
methylation in AUS-1, MEL-1, and D551 cells. Top numbers The Noggin-treated cells could form neurospheres in the
indicate the CpG position relative to the transcription start site. presence of bFGF and EGF in suspension culture (Fig.
Global percentages of methylated cytosines (% Me) are 6b). The average neurosphere formation rates (mean ±
shown. Each row of circles for a given amplicon represents
SEM%) were: AUS-1 cells: 56.1 ± 12.6 (n = 3), ES4CL1:the methylation status of each CpG in one bacterial clone for
80.5 ± 13.8 (n = 2), ES4CL2: 41 ± 1.9 (n = 2), ES4CL3:the region. Ten clones are shown. Open and filled circles indi-
cate unmethylated and methylated CpG dinucleotides, respec- 62.5 ± 4.2 (n = 2), ES4CL4: 23.3 ± 6.7 (n = 2), MR90C2:
tively. 87.5 ± 8.3 (n = 2), and MR90C4: 87.5 ± 8.3 (n = 2). Ef-
ficiency of neurosphere formation from AUS-1 cells was
similar to that from other human iPS cell lines (Fig. 6d).
Further, differentiation toward neurons was achieved bypressed endogenous Oct4, Sox2, and Nanog pluripotent
marker genes, which were not detectable in the parental culturing neurospheres onto laminin-coated plates. βIII-
Tubulin expression was detected in the differentiatedD551 cells (Fig. 2B). Another pluripotent marker, Rex1,
was detectable in AUS-1 line, and weakly detected in cells (Fig. 6c). Neurospheres derived from AUS-1 cells
were induced toward neural crest-like cells by cocultur-AUS-2 and AUS-3. The MEL-1 cells, the AUS cell
lines, and their parental D551 cells all expressed endog- ing them on MEF feeder layers with the addition of
Y27632. Similar to what has been published for hESenous c-Myc and Klf4. We examined the persistent ex-
pression of viral transgenes by RT-PCR and showed that cells, migratory progenitors are observed in the neural
crest induction cultures that express p75 (Fig. 6e) andviral Oct4, Sox2, and c-Myc transgenes were efficiently
silenced; however, viral Klf4 transgene was still ex- can differentiate to neurons expressing the peripheral
marker, Peripherin (Fig. 6f).pressed in the AUS cells. Genomic DNA PCR showed
that all AUS lines harbored integrated transgenes of four
DISCUSSIONtranscription factors (Fig. 2C).
We investigated the DNA methylation status of CpG In summary, the late passage human fibroblasts could
be reprogrammed to a pluripotent state by retroviraldinucleotides in the Oct4 and Nanog promoter regions
in the AUS lines. Two CpG-enriched regions in Oct4 transduction of Yamanaka four transcription factors, al-
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Figure 4. AUS-1 (A) and AUS-2 (B) cells have a normal karyotype (46, XX) at passage of 10 by chromosomal G-banding analysis.
beit with a low infection efficiency. The iPS cells, manaka four reprogramming factors (33,48,54). Practi-
cally, it is difficult to harvest enough cells for iPS cellsnamed AUS cells, were characterized and shown to
share many similar properties to hES cells, including derivation from a 6-mm human skin biopsy in less than
three passages. In this study, we attempted to generatemorphology, cell surface markers, gene expression pro-
files, promoter methylation status, EB formation, tera- human iPS cells from late passage human fibroblasts.
Detroit 551 (D551) cells are human fetal skin fibro-toma formation, and directed neuronal differentiation ca-
pacity. The endogenous self renewal genes (Oct4 and blasts, which have a finite life span of about 25 serial
passages from the tissue of origin as stated in the ATCCNanog) were reactivated and three of the transgenes,
which included c-Myc, were silenced. catalogue. We used cells at passage 23 as target cells for
infection by retroviral delivery of the four reprogram-It has been highly recommended that target cells for
iPS cell derivation be used within three passages in or- ming factors. The infection efficiency was monitored by
retroviral infection of the cells with pMX-GFP. The lowder to avoid replicate senescence (38,47). The reported
efficiency of iPS cell derivation is extremely low, rang- infection rate (24.5%) might reflect that the D551 cells
were not actively proliferating at passage 23, becauseing between 0.01% and 0.2% when using direct viral
infection of adult cells with vectors expressing the Ya- retroviral infectivity is limited to dividing cells (35). Hu-
Figure 5. Hematoxylin and eosin staining of teratoma from AUS cells showed (a) keratinized
epithelium (arrows), (b) cartilage, and (c) secretary epithelium. In in vitro differentiation system,
AUS cells formed embryoid bodies after 7 days in suspension culture (d), further differentiated to
a cyst-like structure (arrow) after 5 days of plating EBs on petri dishes (e). Scale bars: 200 µm.
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Figure 6. In vitro-directed differentiation of AUS-1 cells to neuronal cells and neural crest. (a) AUS-1 cell colonies were treated
with Noggin for 14 days to induce differentiation toward neuroectoderm, as shown by expression of Pax6+ (green); undifferentiated
Oct4+ cells (red) are also observed. (b) Neurospheres formed in suspension culture for 5 days. Neruospheres are morphologically
characterized by containing rosette-like structures formed by clustering of neural stem cells (arrow). (c) Neurospheres plated on
laminin substrate differentiated to neurons in 7 days, as shown expressing of βIII-tubulin. (d) Graph showing efficiency of neurosph-
ere formation for Noggin-treated AUS-1 iPS cells compared with six other Noggin-treated iPS cell lines. (e) AUS-1-derived neu-
rospheres cocultured on a MEF feeder layer, following Y27632 treatment, results in their differentiation to migratory p75+ progeni-
tors, indicative of neural crest-like cells. (f) A subset of p75+ cells further differentiated to neurons expressing the peripheral
neuronal marker, Peripherin. (g) Merged image of (e) and (f) with DAPI counterstaining. Scale bars: 200 µm.
man ES-cell like cells, appearing as colonies, were rec- undergo transcriptional silencing in pluripotent cells.
RT-PCR-specific for retroviral trangene Oct4, Sox2, andognizable from day 19 after two rounds of viral infection
in 48 h. The colonies could be picked up manually at c-Myc transcripts confirmed the effective silencing in
AUS cells. However, silencing was not observed for thearound day 26 and propagated on MEF feeder cells. The
cells were demonstrated as iPS cells with a normal KLF4 transgene. It has been reported that iPS cells made
by retroviral infection often maintain viral gene expres-karyotype by a series of characterization assays.
Unlike the 293T cells used in most other studies to sion (8,39), which is one of the drawbacks in the use of
retroviruses. Therefore, new approaches to deliver re-produce human iPS cells, Plat-A cells were used as ret-
rovirus packaging cells in the present study. Plat-A cells programming factors to the target cells, especially non-
integrated methods, need to be investigated and opti-were generated by stably transfecting two unique pack-
aging constructs into 293T cells (24,34). The two pack- mized (18,19,36,46,53,56,57).
AUS cells could form teratomas and differentiate intoaging constructs use the EF1α promoter to express gag-
pol, or amphotropic env genes. Plat-A cells produce tissue representatives of the three germ layers when in-
jected into immunodeficient mice. Furthermore, whenhigh-titer retroviruses (1 × 106 IU/ml) by transient trans-
fection of pMXs vectors (24). Murine Molony Leukemia maintained in suspension culture conditions, AUS cells
could form EBs, demonstrating their random differentia-Virus (MMLV)-based retroviral vectors are known to
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tion capacity in vitro. Moreover, the AUS cells could be ronal lineage, including definite neuro-ectoderm, neu-
rospheres that could be differentiated to neurons anddirectly differentiated in vitro into neurons and neural
crest-like progenitors, confirming that iPS cells are a neural crest-like progenitors for the first time.
possible source of personalized pluripotent stem cells for
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